公开(公告)号：EP3137504A4

公开(公告)日：2018-02-28

申请号：EP15785500

申请日：2015-04-30

申请人： HANALL BIOPHARMA CO LTD

发明人： KIM SUNG WUK ,  PARK SEUNG KOOK ,  JEONG JAE KAP ,  AHN HYEA KYUNG ,  KIM MIN SUN ,  KIM EUN SUN ,  YONG HAE-YOUNG ,  SHIN DONGOK ,  SONG YEON JUNG ,  YOO TAE HYOUNG

IPC分类号： C07K16/46 ,  A61K39/395 ,  A61P37/00 ,  C07K16/18 ,  C12N15/13 ,  C12N15/63 ,  G01N33/53

CPC分类号： C07K16/283 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/564 ,  G01N33/566 ,  G01N33/6854 ,  G01N2333/70535

摘要： The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.